JnJ to sell remaining 9.5 percent stake in Kenvue
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-05-14 06:00 GMT | Update On 2024-06-20 19:14 GMT
Advertisement
Kenvue, the producer of Tylenol said on Monday that Johnson & Johnson will be selling off its remaining 9.5% stake in the company. This decision follows roughly one year after the healthcare conglomerate separated and listed its consumer health business.
Based on Kenvue stock's last close, the offering of 182.3 million shares would be worth about $3.75 billion, according to Reuters calculation.
Kenvue's shares were down 1.2% in premarket trading. J&J shares were largely unchanged.
J&J finalized the biggest shake-up in its 137-year history to focus on its pharmaceutical and medical devices businesses. The company in May last year sold 172.8 million shares in Kenvue to raise $3.8 billion, and lowered its stake over the next three months.
J&J will exchange its holding to Goldman Sachs and J.P. Morgan Securities for its debt, Kenvue said on Monday. Goldman Sachs, J.P. Morgan and BofA Securities are the joint lead book-running managers.
The Band-Aid maker has focused on its 15 priority brands since the spinoff and earlier this month said it would cut 4% of its global workforce.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.